

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 38/21, C07K 14/52	A1	(11) International Publication Number: WO 00/09152 (43) International Publication Date: 24 February 2000 (24.02.00)
(21) International Application Number: PCT/CA99/00750 (22) International Filing Date: 16 August 1999 (16.08.99) (30) Priority Data: 2,245,224 14 August 1998 (14.08.98) CA (63) Related by Continuation (CON) or Continuation-In-Part (CIP) to Earlier Application US PCT/CA99/00221 (CIP) Filed on 12 March 1999 (12.03.99) (71) Applicant (for all designated States except US): THE UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; Industry Liaison Office, I.R.C. Room 331, 2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): CLARK-LEWIS, Ian [CA/CA]; 2222 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3 (CA). GONG, Jiang-Hong [CA/CA]; 2222 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3 (CA). DURONIO, Vincent [CA/CA]; Dept. of Medicine, The University of British Columbia, 2660 Oak Street, Vancouver, British Columbia V6H 3Z6 (CA).	SALARI, Hassan [CA/CA]; 927 Pacific Drive, Tsawassen, British Columbia V4M 2K2 (CA). (74) Agents: KINGWELL, Brian, G. et al.; Smart & Biggar, Vancouver Centre, Suite 2200, 650 West Georgia Street, Box 11560, Vancouver, British Columbia V6B 4N8 (CA). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: THERAPEUTIC CHEMOKINE RECEPTOR ANTAGONISTS (57) Abstract The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment of multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

THERAPEUTIC CHEMOKINE RECEPTOR ANTAGONISTS

FIELD OF THE INVENTION

The invention relates to the therapeutic uses of chemokine receptor antagonists, including peptide antagonists of CXC chemokine receptor 4 for use in the treatment of cancer and autoimmune disease.

BACKGROUND OF THE INVENTION

Cytokines are soluble proteins secreted by a variety of cells including monocytes or lymphocytes that regulate immune responses. Chemokines are a superfamily of chemoattractant proteins. Chemokines regulate a variety of biological responses and they promote the recruitment of multiple lineages of leukocytes and lymphocytes to a body organ tissue. Chemokines may be classified into two families according to the relative position of the first two cysteine residues in the protein. In one family, the first two cysteines are separated by one amino acid residue, the CXC chemokines, and in the other family the first two cysteines are adjacent, the CC chemokines. Two minor subgroups contain only one of the two cysteines (C) or have three amino acids between the cysteines (CX₃C). In humans, the genes of the CXC chemokines are clustered on chromosome 4 (with the exception of SDF-1 gene, which has been localized to chromosome 10) and those of the CC chemokines on chromosome 17.

The molecular targets for chemokines are cell surface receptors. One such receptor is CXC chemokine receptor 4 (CXCR4), which is a 7 transmembrane protein, coupled to G1 and was previously called LESTR (Loetscher, M., Geiser, T., O'Reilly, T., Zwahlen, R., Baggionlini, M., and Moser, B., (1994) J. Biol. Chem, 269, 232-237), HUMSTR (Federspiel, B., Duncan, A.M.V., Delaney, A., Schappert, K., Clark-Lewis,

I., and Jirik, F.R. (1993) *Genomics* 16, 707-712) and Fusin (Feng, Y., Broeder, C.C., Kennedy, P.E., and Berger, E.A. (1996) HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane G protein-coupled receptor, *Science* 272, 872-877). CXCR4 is widely expressed on cells of hemopoietic origin, and is a major co-receptor with CD4⁺ for human immunodeficiency virus 1 (HIV-1) (Feng, Y., Broeder, C.C., Kennedy, P.E., and Berger, E.A. (1996) HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane G protein-coupled receptor, *Science* 272, 872-877).

Currently, the only known natural ligand for CXCR4 is stromal cell derived factor one (SDF-1). Stromal cell derived factor-1 α (SDF-1 α) (SEQ ID NO: 6) and stromal cell derived factor-1 β (SDF-1 β) (SEQ ID NO: 7) are closely related members (together referred to herein as SDF-1). The native amino acid sequences of SDF-1 α and SDF-1 β are known, as are the genomic sequences encoding these proteins (U.S. Patent No. 5,563,048 issued 8 October 1996, and U.S. Patent No. 5,756,084 issued 26 May 1998).

SDF-1 is functionally distinct from other chemokines in that it is reported to have a fundamental role in the trafficking, export and homing of bone marrow progenitor cells (Aiuti, A., Webb, I.J., Bleul, C., Springer, T., and Guierrez-Ramos, J.C., (1996) *J. Exp. Med.* 185, 111-120 and Nagasawa, T., Hirota, S., Tachibana, K., Takakura N., Nishikawa, S.-I., Kitamura, Y., Yoshida, N., Kikutani, H., and Kishimoto, T., (1996) *Nature* 382, 635-638). SDF-1 is also structurally distinct in that it has only about 22% amino acid sequence identity with other CXC chemokines (Bleul, C.C., Fuhlbrigge, R.C., Casasnovas, J.M., Aiuti, A., and Springer, T.A., (1996) *J. Exp. Med.* 184, 1101-1109). SDF-1 appears to be produced constitutively by several cell

types, and particularly high levels are found in bone-marrow stromal cells (Shirozu, M., Nakano, T., Inazawa, J., Tashiro, K., Tada, H. Shinohara, T., and Honjo, T., (1995) Genomics, 28, 495-500 and Bleul, C.C., Fuhlbrigge, R.C.,

5 Casasnovas, J.M., Aiuti, A., and Springer, T.A., (1996) J. Exp. Med. 184, 1101-1109). A basic physiological role for SDF-1 is implied by the high level of conservation of the SDF-1 sequence between species. In vitro, SDF-1 stimulates chemotaxis of a wide range of cells including monocytes and

10 bone marrow derived progenitor cells (Aiuti, A., Webb, I.J., Bleul, C., Springer, T., and Guierrez-Ramos, J.C., (1996) J. Exp. Med. 185, 111-120 and Bleul, C.C., Fuhlbrigge, R.C., Casasnovas, J.M., Aiuti, A., and Springer, T.A., (1996) J. Exp. Med. 184, 1101-1109). Particularly notable is its

15 ability to stimulate a high percentage of resting and activated T-lymphocytes (Bleul, C.C., Fuhlbrigge, R.C., Casasnovas, J.M., Aiuti, A., and Springer, T.A., (1996) J. Exp. Med. 184, 1101-1109 and Campbell, J.J., Hendrick, J., Zlotnik, A., Siani, M.A., Thompson, D.A., and Butcher, E.C.,

20 (1998) Science, 279 381-383).

The 3-dimensional crystallographic structure of SDF-1 has been described (Crump, M., Gong J.-H., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana-Seisdedos, F.,

25 Virelizier, J.-L., Baggiolini, M., Sykes, B.D., and Clark-Lewis, I., (1997) EMBO J., 16, 6996-7007). Structure-activity analysis of SDF-1 (Crump, M., Gong J.-H., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana-Seisdedos, F., Virelizier, J.-L., Baggiolini, M., Sykes, B.D., and Clark-

30 Lewis, I., (1997) EMBO J., 16, 6996-7007) and indicates that although N-terminal residues 1-8 or 1-9 are involved in receptor binding, the 1-8 and 1-9 peptides alone exhibited no in vitro activity indicative of receptor binding, supporting a reported conclusion that the peptides do not assume the

conformation necessary for binding to the receptor. This result was taken to imply that the remainder of the protein scaffold, and/or various consensus receptor binding sites elsewhere in the protein are important for mediating the conformational requirements for N-terminal binding to the receptor (Crump, M., Gong J.-H., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana-Seisdedos, F., Virelizier, J.-L., Baggiolini, M., Sykes, B.D., and Clark-Lewis, I., (1997) EMBO J., 16, 6996-7007). Based on these results, a two-site model has been proposed for SDF-1 binding to CXCR4, involving two binding sites in residues 1-17, an N-terminal site and an upstream RFFESH site (Crump, M., Gong J.-H., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana-Seisdedos, F., Virelizier, J.-L., Baggiolini, M., Sykes, B.D., and Clark-Lewis, I., (1997) EMBO J., 16, 6996-7007). The two putative binding sites have been characterised by the sequence: KPVSLSYR-CPC-RFFESH (SEQ ID NO: 1), in which the two putative binding sites are joined by the CXC motif that characterises the whole CXC chemokine family (Crump, M., Gong J.-H., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana-Seisdedos, F., Virelizier, J.-L., Baggiolini, M., Sykes, B.D., and Clark-Lewis, I., (1997) EMBO J., 16, 6996-7007). These two putative binding regions have been identified as being important in other CC and CXC chemokines (Crump, M., Gong J.-H., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana-Seisdedos, F., Virelizier, J.-L., Baggiolini, M., Sykes, B.D., and Clark-Lewis, I., (1997) EMBO J., 16, 6996-7007 and Crump, M., Gong J.-H., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana-Seisdedos, F., Virelizier, J.-L., Baggiolini, M., Sykes, B.D., and Clark-Lewis, I., (1997) EMBO J., 16, 6996-7007). This is consistent with the finding that although N-terminal regions of a wide variety of chemokines are critical for receptor activation, N-terminal peptides of chemokines other than SDF-1 have been reported to lack receptor binding activity and not to be receptor agonists (Crump, M., Gong J.-H., Loetscher, P.,

Rajaratnam, K., Amara, A., Arenzana-Seisdedos, F., Virelizier, J.-L., Baggiolini, M., Sykes, B.D., and Clark-Lewis, I., (1997) EMBO J., 16, 6996-7007 and Crump, M., Gong J.-H., Loetscher, P., Rajaratnam, K., Amara, A., Arenzana-Seisdedos, F., Virelizier, J.-L., Baggiolini, M., Sykes, B.D., and Clark-Lewis, I., (1997) EMBO J., 16, 6996-7007).

Consistent with the fact that CXCR4 is a major co-receptor for HIV-1, SDF-1 blocks HIV-1 entry into CD4⁺ cells Oberlin, E., Amara, A., Bachelier, F., Bessia, C., Virelizier, J.-L., Arenzana-Seisdedos, F., Schwartz, O., Heard, J.-M., Clark-Lewis, I., Legler, D.F., Loetscher, M., Baggiolini, M., and Moser, B., (1996) Nature, 382, 833-835 and Bleul, C.C., Farzan, M., Choe, H., Parolin, C., Clark-Lewis, I., Sodroksi, J., and Springer, T.A., (1996) Nature, 382, 829-833). Efforts have been made to identify SDF-1 derived peptides that interfere selectively with HIV entry, and not with SDF-1 signalling (Heveker, N. et al., 1998, Current Biology 8(7):369-376). A wide range of potential CXCR4 binding fragments of SDF-1 have been proposed for use in blocking HIV infection (WO 9728258, published 7 August 1997; WO 9804698, published 5 February 1998). As these references make clear, the anti-HIV activity of SDF-1, or fragments of SDF-1, does not depend on antagonism of the CXCR4 receptor.

Interferon gamma is an important cytokine that is released by activated T-lymphocytes (T-cells) and acts as a potent immunomodulator. Interferon gamma production by T-cells in vivo may cause other cells in the body to release additional cytokines, enzymes and antibodies that are capable of modulating many aspects of an immune response. Agents which effect the ability of activated T-cells to produce interferon gamma are characterized as immunomodulators.

Autoimmune diseases are a group of illnesses generally understood to be caused by the over-production of cytokines, lymphotoxins and antibodies by white blood cells, including in particular T-cells. During an autoimmune reaction, T-cells are understood to release chemical mediators such as interferon gamma which lead to the development of pathological symptoms of autoimmune reaction. A treatment for autoimmune diseases may therefore involve the use of agents capable of inhibiting release of interferon gamma from T-cells. Such autoimmune diseases may include, for example, Multiple Sclerosis (MS), Guillain-Barre Syndrome, Amotrophic Lateral Sclerosis, Parkinson's disease, Alzheimer's disease, Gout, Lupus, and any other human illnesses that T-cells play a major role in, such as tissue graft rejection.

Interferon beta is a cytokine that has found to have therapeutic application in the treatment of a variety of autoimmune diseases. In autoimmune diseases such as MS, the activation of Th1 type T-cells is thought to be a primary component of the autoimmune response. In MS, the autoimmune response attacks the myelin sheath neuronal axons. One of the classical markers of Th1 cell activation is the production of interferon gamma. In the development of interferon beta as a therapeutic agent for the treatment of MS, studies were conducted to demonstrate the ability of interferon beta to decrease the rate of production of interferon gamma from lymphocytes in vitro (Ann. Neurol. 1998; 44: 27-34 and Neurology 1998; 50: 1294-1300). The reduction of interferon gamma release by treatment with interferon beta is an indication of the effectiveness of interferon beta in the treatment of MS. There is a continuing need for other agents that inhibit the production of interferon gamma, particularly agents for use in the treatment of autoimmune disease,

including agents that may work synergistically to enhance the effect of existing agents such as interferon beta.

5 Solid tumour growth is generally angiogenesis (neovascularization)-dependent, and angiogenesis inhibitors have therefore been used as agents for the treatment of solid tumours and metastasis. Endothelial cells (EC) in the vasculature play an essential role in angiogenesis, and there is accordingly a need for therapeutic agents that target this
10 activity. The proliferation, migration and differentiation of vascular endothelial cells during angiogenesis is understood to be modulated in both normal and disease states by the complex interactions of a variety of chemokines and chemokine receptors. CXCR4 is expressed on vascular EC, and in such
15 cells is reportedly the most abundant receptor amongst all examined chemokine receptors (Gupta, et al, 1998).

SUMMARY OF THE INVENTION

In one aspect, the invention provides a variety of
20 therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment of
25 multiple sclerosis, treatment of other neurological diseases, treatment of cancer, and regulation of angiogenesis. In some aspects of the invention, CXCR4 inhibitors may be used, particularly in the treatment of multiple sclerosis, with or without beta interferon. The invention provides corresponding
30 methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or

carrier, as described above. The therapeutic composition may advantageously be soluble in an aqueous solution at a physiologically acceptable pH.

5 In alternative embodiments, the CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analog or pharmacologically acceptable salt of SDF-1. In some
10 amino acid sequence KGVLSYRC-R₁ (SEQ ID NO: 2) wherein R₁ is selected from the group consisting of hydrogen and polypeptides homologous to at least a portion of SDF-1.

In a further embodiment, the peptide compound may
15 comprise a dimerized N-terminal amino acid sequence. For example, an SDF-1(1-8)₂ dimer may be used, as represented here with the second polypeptide segment of the dimer written from the carboxyl to the amino end: KGVLSYR-X-RYSLSVGK (a dimer of SEQ ID NO:3, as shown in Fig. 14). In another embodiment, the
20 peptide compound may further comprise a dimerized N-terminal amino acid SDF-1(1-9)₂, represented here with the second dimer written from the carboxyl to the amino end): KGVLSYRC-X-CRSLSVGK, (a dimer of SEQ ID NO:4, as shown in Fig. 14). In such dimers, X may be a lysine amino acid wherein both the
25 α - and ϵ -amino groups are associated with amide bond formation and the lysyl carboxyl group may be protected. Similarly, X may be other moieties in which two amino groups are used to form a linkage between the peptides, such as ornithine or L-amino-N-butyric acid. The linkage may be
30 between terminal carboxyl groups, such as between the terminal carboxyl groups of the In an alternative embodiment, X may be a benzene ring in which the peptides are attached at adjoining carbons on the ring. Alternatively, X may be any bridge-forming moiety that covalently links peptides so that a

plurality of peptides are joined by the bridge to provide a plurality of N-terminals in the compounds.

BRIEF DESCRIPTION OF FIGURES

5 Figure 1: Sequence of native SDF-1 (prior art).

Figure 2: Chemoattractant activity of SDF-1 peptides. Concentration dependent migration of CEM cells (a); and T-lymphocytes (b) in response to the SDF-1 peptides:
10 1-8 (\square); 1-9 (Δ); 1-9 dimer (\blacktriangle); and 1-9[Aba] (\boxplus);
and in response to native SDF-1 (\bullet). The data shown are the means \pm SD of migrated cells. Similar results were obtained in two additional experiments.

15 Figure 3: Chemotaxis inhibition by chemokine antagonists. CEM cell migration induced by SDF-1(1-9) peptide (10 μ M) in the presence of the indicated concentrations of the SDF-1 antagonist, SDF-1(1-67)[P2G] (\boxminus); or the IL-8 antagonist, IL-8(6-72) (\oplus). Migrations is expressed as
20 percent of the response obtained in the absence of antagonist (control, \blacksquare). The data shown are the means \pm SD of duplicate determinations from two separate experiments.

Figure 4: Receptor binding of SDF-1 peptides.
25 Competition for specific binding of 125 I-SDF-1 (4 nM) to CEM cells by 1-8 (\square); 1-9 (Δ); 1-9 dimer (\blacktriangle); 1-9[Aba-9] (\boxplus); native SDF-1 (\bullet). The percentage specific cpm bound in the absence of competitor (\square), is shown. Representative results from two to six experiments.

30

Figure 5: Receptor selectivity of the SDF-1 peptides. T-lymphocytes that were loaded with Fura-2 were sequentially stimulated with chemokines and SDF-1(1-9) and the

resulting $(Ca^{2+})_i$ -dependent fluorescence changes were recorded.

(a) Cross-desensitization of SDF-1 and the 1-9 peptide.

(b) Lack of desensitization of SDF-1(1-9) by the indicated CXC or CC chemokines. The chemokines were added at 100 nM, except
5 for SDF-1 which was added at 1 nM, followed by addition of the 1-9 peptide (30 μ M) after 60 s. The results shown are representative of two to three independent experiments.

Figure 6: Line-1 lung carcinoma (5×10^5 /50 μ l in PBS
10 buffer) was injected subcutaneously on the back of each BALB/c mouse (male, 6-8 weeks old, purchased from Jackson Labs, Bar Harbour, ME). The mice were blindly divided into four groups (three of each group). Immediately after the implantation, the mice received ip. or sc. injection of SDF-1P2G (9 mg/kg
15 in 100 μ l PBS buffer). Control mice were injected with the same dose of bovine serum albumin (BSA) or PBS buffer only. The injection was once daily. The size of the tumor was recorded on a daily basis. On day 16, the mass of tumor was determined. The sections of tumor and lung were stained and
20 morphologically observed for blood vessels and metastasis. Shown is the mean value \pm SEM of the tumor size.

Figure 7: Line-1 carcinoma cells (1×10^6 /mouse) were implanted (sc.) as described above. The mice were blindly
25 divided into 4 groups (2 of each), and treated with SDF-1P2G (9mg/kg), or the dimer form of SDF(1-9)P2G (18 mg/kg). The control groups were injected with PBS buffer alone or BSA. The injection was ip., daily. The size and mass of tumors were determined as above. On day 12 the histology of the
30 tumor was studied. Shown is the mean \pm SEM of the tumor size.

Figure 8: The mass of the tumor from the experiment in Figure 7.

Figure 9: Inhibition of mouse lung carcinoma (Lewis lung carcinoma) growth by full length SDF-1 antagonist or by short peptide antagonist.

5 Figure 10: Mass of tumor (Lewis lung carcinoma) on day 12.

Figure 11: Effect of SDF-1 on ConA-stimulated Interferon-gamma production in human T-cells.

10

Figure 12: Effect of SDF-1 antagonist on ConA-stimulated interferon-gamma production in human T-cells.

Figure 13: Effect of 10 nM SDF-1 and antagonist on 10
15 nM ConA-stimulated Interferon-gamma production.

Figure 14: The structures of dimer peptide antagonist compounds.

20 Figures 15 shows the effect of the SDF-1 derived peptide SDF-1(1-8[P2G]), on interferon gamma (IFN-g) release from concanavilin A activated mixed human lymphocytes.

Figures 15, 17, 19, 21 and 23 show the effect of various
25 SDF-1 derived peptides on interferon gamma (IFN-g) release from concanavilin A activated mixed human lymphocytes, where the peptides are respectively: Fig. 15 SDF-1(1-8[P2G]),K (i.e. the linking group is lysine); Fig. 17 SDF-1(1-8),K; Fig. 19 SDF-1(1-9[P2G]),; Fig. 21 SDF-1(1-8)K(6-8) (i.e. a lysine linking
30 peptides 1-8 and 6-8 of SDF-1); Fig. 23 SDF-1(1-17)Ala9,11 (i.e. alanine substituted for cystine at positions 9 and 11).

Figures 16, 18, 20, 22 and 24 show the effect of various SDF-1 derived peptides on tumor necrosis factor alpha (TNF-a)
35 release by Con. A activated mixed human lymphocytes, where the

peptides are respectively: Fig. 16 SDF-1(1-8[P2G]),K (i.e. the linking group is lysine); Fig. 18 SDF-1(1-8),K; Fig. 20 SDF-1(1-9[P2G]),; Fig. 22 SDF-1(1-8)K(6-8) (i.e. a lysine linking peptides 1-8 and 6-8 of SDF-1); Fig. 24 SDF-1(1-17)Ala9,11
5 (i.e. alanine substituted for cystine at positions 9 and 11).

Figure 25 shows the effect of the SDF-1 derived peptide SDF-1(1-9[P2G]), in an established animal model of MS, experimental autoimmune encephalomyelitis (EAE) in mice.

10

DETAILED DESCRIPTION OF THE INVENTION

In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat, or produce medicaments to treat, a variety of autoimmune diseases. Such diseases
15 include multiple sclerosis, Guillain-Barre syndrome (GBS), Amyotrophic lateral sclerosis (ALS), and other diseases of nerves, rheumatoid arthritis, psoriasis, diabetes type I, ulcerative colitus, gout, lupus, and transplant rejection.

20 In accordance with one aspect of the invention, antagonists of CXCR4 may be used therapeutically to regulate angiogenesis and cell growth in human pathological diseases including cancers such as lymphoma and carcinoma, as well as restonosis. In one embodiment, as exemplified herein, two
25 peptide CXCR4 antagonists have been used to inhibit angiogenesis and tumor growth in mouse models of mammalian cancers.

The SDF-1 antagonists of the invention may be used to
30 inhibit gamma interferon production by activated T-cells. This may have particular application in the treatment of autoimmune disease, in which production of gamma interferon by T-cells is an art recognised disease marker. Examples of diseases which are known to be mediated by interferon gamma are MS (Proc.

Natl. Acad Sci. Vol. 95; 675-680; 1998), Guillian-barre (Ann Neurol, Vol. 27; S57-S63; 1990), Autoimmune Kidney damage (J. Immunol. 161; 494-503; 1998), arthritis (Immunol. 95; 480-487; 1998) and various other neurological diseases (Acta. Neurol. Scand. 90; 19-25; 1994). More general descriptions of interferon gamma mediated autoimmune diseases can be found in J. Immunol. 161; 6878-6884; 1998 and J. Exp. Med. 186; 385-391; 1997. In one embodiment of the invention, the peptide antagonist SDF-1(1-67)[P2G] has, for example, been used to inhibit production of gamma interferon by T-cells. Also, the peptide SDF-1 (1-9) P2G reduced gamma interferon release from human T-cells (ie. these peptides are regulators of human autoimmune diseases).

The invention also provides an assay to identify CXCR4 inhibitors that may be used to inhibit gamma interferon production, particularly in autoimmune disease. An embodiment of such an assay is disclosed in Example 2 herein.

In one embodiment, the assay comprises concanavalin A stimulated T-cells which release interferon gamma. In the assay, the T-cells are contacted with the putative CXCR4 antagonist and the degree of interferon gamma release is measured. The compounds to be assayed for antagonistic activity may be selected for their ability to decrease the amount of interferon gamma production.

Also within the scope of the present invention is an assay for compounds that inhibit angiogenesis. In the assay, a vascularized tumor in a mouse is contacted with the putative CXCR4 antagonist and the degree of vascularization is measured. The compounds to be assayed for anti-angiogenesis activity may be selected for their ability to decrease the amount of vascularization in a tumor.

35

In various aspects, the present invention utilizes CXCR4 antagonists. In some embodiments, the CXCR4 antagonists for use in the invention may be substantially purified peptide fragments, modified peptide fragments, analogues or pharmacologically acceptable salts of either SDF-1 α or SDF-1 β . SDF-1 derived peptide antagonists of CXCR4 may be identified by known physiological assays and a variety of synthetic techniques (such as disclosed in Crump et al., 1997, The EMBO Journal 16(23) 6996-7007; and Heveker et al., 1998, Current Biology 8(7): 369-376; each of which are incorporated herein by reference). Such analogues of SDF-1 include homologs of native SDF-1, such as naturally occurring isoforms or genetic variants, or SDF-1 derived polypeptides having substantial sequence similarity to SDF-1, such as 40% sequence identity, 60% sequence identity or preferably 80% sequence identity to at least a portion of the native SDF-1 sequence, provided they have CXCR4 antagonistic activity. In some embodiments, chemically similar amino acids may be substituted for amino acids in the native SDF-1 sequence (to provide conservative amino acid substitutions). In some embodiments, peptides having an N-terminal LSY sequence motif within 10, or preferably within 7, amino acids of the N-terminus, and/or an N-terminal RFFESH (SEQ ID NO:5) sequence motif within 20 amino acids of the N-terminus may be used provided they have CXCR4 antagonistic activity. The single letter amino acid code and the three letter amino acid code are used interchangeably herein. One family of such peptide antagonist candidates has a KP motif as an N-terminal and an LSY motif at amino acids 5-7. Alternative peptides further include the RFFESH (SEQ ID NO: 5) motif at amino acids 12-17. In alternative embodiments, the LSY motif is located at positions 3-5 of a peptide. The invention also provides peptide dimers having two amino acid sequences, which may each have the foregoing sequence elements, attached by a disulfide bridge within 20, or

preferably within 10, amino acids of the N terminus, linking cysteine residues or α -aminobutric acid residues.

In one aspect, the invention provides CXCR4 antagonists
5 in which glycine is substituted for proline at amino acid position 2. The full (67 amino acid long) versions of this analog, designated SDF-1(1-67)[P2G], is a potent CXCR4 receptor antagonist (Crump et al., 1997, The EMBO Journal 16(23) 6996-7007). A variety of small SDF-1 peptide analogues
10 may also be used as CXCR4 antagonists. One such peptide is a dimer of amino acids 1-9, with glycine substituted for proline in each member of the dimer at position 2, in which the amino acid chains are joined by a disulphide bond between each of the cysteines at position 9 in each sequence (designated SDF-
15 1(1-9[P2G])). SDF-1(1-9[P2G]), lacked detectable chemotactic activity (Figure 2a), but it competed for SDF-1 binding with similar affinity to a SDF-1(1-9)₂ dimer (Figure 4). The SDF-1(1-9[P2G])₂ dimer inhibited SDF-1 activity in a dose dependent manner (Figure 3b). 50 μ M of SDF-1(1-9[P2G])₂ dimer
20 was required to inhibit the activity of 10nM of SDF-1 by 50%, a ratio of 5,000.

The invention provides pharmaceutical compositions containing CXCR4 antagonists. In one embodiment, such
25 compositions include a CXCR4 antagonist compound in a therapeutically or prophylactically effective amount sufficient to alter, and preferably inhibit, production of gamma interferon, and a pharmaceutically acceptable carrier. In another embodiment, the composition includes a CXCR4
30 antagonist compound in a therapeutically or prophylactically effective amount sufficient to inhibit the angiogenesis, preferably angiogenesis associated with carcinomas and lymphomas, and a pharmaceutically acceptable carrier. A "therapeutically effective amount" refers to an amount

effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as reduction or reversal of angiogenesis in the case of cancers, or reduction or inhibition of gamma interferon production from T-cells in the case of autoimmune diseases. A therapeutically effective amount of CXCR4 antagonist may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the CXCR4 antagonist to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of the CXCR4 antagonist are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as preventing or inhibiting the rate of metastasis of a tumour or the onset of bouts or episodes of multiple sclerosis. A prophylactically effective amount can be determined as described above for the therapeutically effective amount. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.

In particular embodiments, a preferred range for therapeutically or prophylactically effective amounts of CXCR4 antagonist may be 0.1 nM-0.1M, particularly 0.1 nM-0.05M, more particularly 0.05 nM-15 μ M and most particularly 0.01 nM-10 μ M.

It is to be noted that dosage values may vary with the severity of the condition to be alleviated, especially with multiple sclerosis. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgement of the person administering or

supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.

5

The amount of active compound in the composition may vary according to factors such as the disease state, age, sex, and weight of the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, a
10 single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease
15 of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in
20 association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations
25 inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

As used herein "pharmaceutically acceptable carrier" or "excipient" includes any and all solvents, dispersion media,
30 coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. In one embodiment, the carrier is suitable for parenteral administration. Alternatively, the carrier can be suitable for intravenous, intraperitoneal,
35 intramuscular, sublingual or oral administration.

Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for
5 pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into
10 the compositions.

Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion,
15 liposome, or other ordered structure suitable to high drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The
20 proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as
25 mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin. Moreover, the CXCR4 antagonists can be administered
30 in a time release formulation, for example in a composition which includes a slow release polymer. The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery
35 systems. Biodegradable, biocompatible polymers can be used,

such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PLG). Many methods for the preparation of such formulations are patented or generally
5 known to those skilled in the art.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g. CXCR4 antagonist) in the required amount in an appropriate solvent with one or a
10 combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the
15 case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

20

In accordance with an alternative aspect of the invention, a CXCR4 antagonist may be formulated with one or more additional compounds that enhance the solubility of the CXCR4 antagonist.

25

Another aspect of the invention pertains to a method for selecting CXCR4 antagonists which bind to the CXCR4 receptor. In the method, a test compound is contacted with activated human T-cells, the production of gamma interferon is measured
30 and a CXCR4 antagonist is selected based on the ability of the test compound to decrease or inhibit the production of gamma interferon. The test compound may be a substantially purified peptide fragment, modified fragment, analog or pharmacologically acceptable salt of either SDF-1 α or

SDF-1 β . In a preferred embodiment, the test compound is contacted with a molar excess amount of the T-cells. The amount and/or rate of gamma interferon production in the presence of the test compound can be determined by a suitable assay, as described elsewhere herein. In the presence of a test compound that inhibits gamma interferon production, the production of gamma interferon is reduced compared to when the CXCR4 antagonist is absent.

CXCR4 antagonist compounds of the invention include SDF-1 derivatives, such as C-terminal hydroxymethyl derivatives, O-modified derivatives (e.g., C-terminal hydroxymethyl benzyl ether), N-terminally modified derivatives including substituted amides such as alkylamides and hydrazides and compounds in which a C-terminal phenylalanine residue is replaced with a phenethylamide analogue (e.g., Ser-Ile-phenethylamide as an analogue of the tripeptide Ser-Ile-Phe).

Within a CXCR4 antagonist compound of the invention, a peptidic structure (such as an SDF-1 derived peptide) maybe coupled directly or indirectly to at least one modifying group. The term "modifying group" is intended to include structures that are directly attached to the peptidic structure (e.g., by covalent coupling), as well as those that are indirectly attached to the peptidic structure (e.g., by a stable non-covalent association or by covalent coupling to additional amino acid residues, or mimetics, analogues or derivatives thereof, which may flank the SDF-1 core peptidic structure). For example, the modifying group can be coupled to the amino-terminus or carboxy-terminus of an SDF-1 peptidic structure, or to a peptidic or peptidomimetic region flanking the core domain. Alternatively, the modifying group can be coupled to a side chain of at least one amino acid residue of a SDF-1 peptidic structure, or to a peptidic or peptido-

WO 00/09152

PCT/CA99/00750

mimetic region flanking the core domain (e.g., through the epsilon amino group of a lysyl residue(s), through the carboxyl group of an aspartic acid residue(s) or a glutamic acid residue(s), through a hydroxy group of a tyrosyl residue(s), a serine residue(s) or a threonine residue(s) or other suitable reactive group on an amino acid side chain). Modifying groups covalently coupled to the peptidic structure can be attached by means and using methods well known in the art for linking chemical structures, including, for example, amide, alkylamino, carbamate or urea bonds.

The term "modifying group" is intended to include groups that are not naturally coupled to natural SDF-1 peptides in their native form. Accordingly, the term "modifying group" is not intended to include hydrogen. The modifying group(s) is selected such that the CXCR4 antagonist compound alters, and preferably inhibits, gamma interferon production.

The invention also provides "modifying groups" selected such that the CXCR4 antagonist compound inhibits angiogenesis of tumours when contacted with the T-cells or the tumour respectively.

In a preferred embodiment, the modifying group(s) comprises a cyclic, heterocyclic or polycyclic group. The term "cyclic group", as used herein, is intended to include cyclic saturated or unsaturated (i.e., aromatic) group having from about 3 to 10, preferably about 4 to 8, and more preferably about 5 to 7, carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl. Cyclic groups may be unsubstituted or substituted at one or more ring positions. Thus, a cyclic group may be substituted with, e.g., halogens, alkyls, cycloalkyls, alkenyls, alkynyls, aryls, heterocycles, hydroxyls, aminos, nitros, thiols amines, imines, amides, phosphonates,

phosphines, carbonyls, carboxyls, silyls, ethers, thioethers, sulfonyls, sulfonates, selenoethers, ketones, aldehydes, esters, -CF₃, -CN, or the like.

5 The term "heterocyclic group" is intended to include cyclic saturated or unsaturated (i.e., aromatic) group having from about 3 to 10, preferably about 4 to 8, and more preferably about 5 to 7, carbon atoms, wherein the ring structure includes about one to four heteroatoms. Heterocyclic
10 groups include pyrrolidine, oxolane, thiolane, imidazole, oxazole, piperidine, piperazine, morpholine. The heterocyclic ring can be substituted at one or more positions with such substituents as, for example, halogens, alkyls, cycloalkyls, alkenyls, alkynyls, aryls, other heterocycles, hydroxyl,
15 amino, nitro, thiol, amines, imines, amides, phosphonates, phosphines, carbonyls, carboxyls, silyls, ethers, thioethers, sulfonyls, selenoethers, ketones, aldehydes, esters, -CF₃, -CN, or the like. Heterocycles may also be bridged or fused to other cyclic groups as described below.

20

 The term "polycyclic group" as used herein is intended to refer to two or more saturated or unsaturated (i.e., aromatic) cyclic rings in which two or more carbons are common to two adjoining rings, e.g., the rings are "fused rings". Rings that
25 are joined through non-adjacent atoms are termed "bridged" rings. Each of the rings of the polycyclic group can be substituted with such substituents as described above, as for example, halogens, alkyls, cycloalkyls, alkenyls, alkynyls, hydroxyl, amino, nitro, thiol, amines, imines, amides,
30 phosphonates, phosphines, carbonyls, carboxyls, silyls, ethers, thioethers, sulfonyls, selenoethers, ketones, aldehydes, esters, -CF₃, -CN, or the like.

 The term "alkyl" refers to the radical of saturated
35 aliphatic groups, including straight chain alkyl groups,

branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In preferred embodiments, a straight chain or branched chain alkyl has 20 or fewer carbon atoms in its backbone (e.g., C₁-C₂₀ for straight chain, C₃-C₂₀ for branched chain), and more preferably 10 or fewer. Likewise, preferred cycloalkyls have from 4-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure. Unless the number of carbons is otherwise specified, "lower alkyl" as used herein means an alkyl group, as defined above, but having from one to six carbon atoms in its backbone structure. Likewise, "lower alkenyl" and "lower alkynyl" have similar chain lengths. Preferred alkyl groups are lower alkyls. In preferred embodiments, a substituent designated herein as alkyl is a lower alkyl.

The term "alkyl" (or "lower alkyl") as used throughout the specification and claims is intended to include both "unsubstituted alkyls" and "substituted alkyls", the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, halogen, hydroxyl, carbonyl (such as carboxyl, ketones (including alkylcarbonyl and arylcarbonyl groups), and esters (including alkyloxycarbonyl and aryloxycarbonyl groups)), thiocarbonyl, acyloxy, alkoxy, phosphoryl, phosphonate, phosphinate, amino, acylamino, amido, amidine, imino, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, heterocyclyl, aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. For instance, the substituents of a substituted alkyl may include substituted and unsubstituted forms of aminos, azidos, iminos, amidos, phosphoryls (including phosphonates and phosphinates),

sulfonyls (including sulfates, sulfonamidos, sulfamoyls and sulfonates), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), -CF₃, -CN and the like. Exemplary substituted alkyls
5 are described below. Cycloalkyls can be further substituted with alkyls, alkenyls, alkoxys, alkylthios, aminoalkyls, carbonyl-substituted alkyls, -CF₃, -CN, and the like.

The terms "alkenyl" and "alkynyl" refer to unsaturated
10 aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.

The term "aralkyl", as used herein, refers to an alkyl or
15 alkylenyl group substituted with at least one aryl group (e.g., an aromatic or heteroaromatic group). Exemplary aralkyls include benzyl (i.e., phenylmethyl), 2-naphthylethyl, 2-(2-pyridyl)propyl, 5-dibenzosuberyl, and the like.

The term "alkylcarbonyl", as used herein, refers to -
20 C(O)-alkyl. Similarly, the term "arylcabonyl" refers to -C(O)-aryl. The term "alkyloxycarbonyl", as used herein, refers to the group -C(O)-O-alkyl, and the term "aryloxycarbonyl" refers to -C(O)-O-aryl. The term "acyloxy" refers to -O-C(O)-
25 R₁, in which R₁ is alkyl, alkenyl, alkynyl, aryl, aralkyl or heterocyclyl.

The term "amino", as used herein, refers to -N(R₈)(R₉),
in which R₈ and R₉ are each independently hydrogen, alkyl,
30 alkyenyl, alkynyl, aralkyl, aryl, or R₈ and R₉, together with the nitrogen atom to which they are attached, form a ring having 4-8 atoms. Thus, the term "amino", as used herein, includes unsubstituted, monosubstituted (e.g., monoalkylamino or monoarylamino), and disubstituted (e.g., dialkylamino or
35 alkylarylamino) amino groups. The term "amido" refers to -

$C(O)-N(R_8)(R_9)$, in which R_8 and R_9 are as defined above. The term "acylamino" refers to $-N(R'_8)C(O)-R_7$, in which R_7 is as defined above and R'_8 is alkyl.

5 As used herein, the term "nitro" means $-NO_2$; the term "halogen" designates $-F$, $-Cl$, $-Br$ or $-I$; the term "sulfhydryl" means $-SH$; and the term "hydroxyl" means $-OH$.

10 The term "aryl" as used herein includes 5-, 6- and 7-membered aromatic groups that may include from zero to four heteroatoms in the ring, for example, phenyl, pyrrolyl, furyl, thiophenyl, imidazolyl, oxazole, thiazolyl, triazolyl, pyrazolyl, pyridyl, pyrazinyl, pyridazinyl and pyrimidinyl, and the like. Those aryl groups having heteroatoms in the ring
15 structure may also be referred to as "aryl heterocycles" or "heteroaromatics". The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro,
20 sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, $-CF_3$, $-CN$, or the like. Aryl groups can also be part of a polycyclic group. For example, aryl groups
25 include fused aromatic moieties such as naphthyl, anthracenyl, quinolyl, indolyl, and the like.

30 A CXCR4 antagonist compound can be modified at its carboxy terminus with a cholyl group according to methods known in the art (see e.g., Wess, G. et al. (1993) Tetrahedron Letters, 34:817-822; Wess, G. et al. (1992) Tetrahedron Letters 33:195-198; and Kramer, W. et al. (1992) J. Biol. Chem. 267:18598-18604). Cholyl derivatives and analogues can also be used as modifying groups. For example, a preferred
35 cholyl derivative is Aic (3-(O-aminoethyl-iso)-cholyl), which

has a free amino group that can be used to further modify the CXCR4 antagonist compound.

In one embodiment, the modifying group may be a "biotinyl structure", which includes biotinyl groups and analogues and derivatives thereof (such as a 2-iminobiotinyl group). In another embodiment, the modifying group can comprise a "fluorescein-containing group"; such as a group derived from reacting an SDF-1 derived peptidic structure with 5-(and 6)-carboxyfluorescein, succinimidyl ester or fluorescein isothiocyanate. In various other embodiments, the modifying group(s) can comprise an N-acetylneuraminyl group, a trans-4-cotininecarboxyl group, a 2-imino-1-imidazolidineacetyl group, an (S)-(-)-indoline-2-carboxyl group, a (-)-menthoxyacetyl group, a 2-norbornaneacetyl group, a γ -oxo-5-acenaphthenebutyryl, a (-)-2-oxo-4-thiazolidinecarboxyl group, a tetrahydro-3-furoyl group, a 2-iminobiotinyl group, a diethylenetriaminepentaacetyl group, a 4-morpholinecarbonyl group, a 2-thiopheneacetyl group or a 2-thiophenesulfonyl group.

Modifying groups may include groups comprising biotinyl structures, fluorescein-containing groups, a diethylene-triaminepentaacetyl group, a (-)-menthoxyacetyl group, and a N-acetylneuraminyl group. More preferred modifying groups those comprising a cholyl structure or an iminiobiotinyl group.

In addition to the cyclic, heterocyclic and polycyclic groups discussed above, other types of modifying groups can be used in a CXCR4 antagonist of the invention. For example, small hydrophobic groups may be suitable modifying groups. An example of a suitable non-cyclic modifying group is an acetyl group.

WO 00/09152

PCT/CA99/00750

A CXCR4 antagonist compound of the invention can be further modified to alter the specific properties of the compound while retaining the ability of the compound to either
5 inhibit angiogenesis or inhibit gamma interferon production. For example, in one embodiment, the compound is further modified to alter a pharmacokinetic property of the compound, such as in vivo stability or half-life. In another embodiment, the compound is further modified to label the compound with a
10 detectable substance. In yet another embodiment, the compound is further modified to couple the compound to an additional therapeutic moiety.

To further chemically modify the compound, such as to
15 alter its pharmacokinetic properties, reactive groups can be derivatized. For example, when the modifying group is attached to the amino-terminal end of the SDF-1 core domain, the carboxy-terminal end of the compound can be further modified. Preferred C-terminal modifications include those which reduce
20 the ability of the compound to act as a substrate for carboxypeptidases. Examples of preferred C-terminal modifiers include an amide group, an ethylamide group and various non-natural amino acids, such as D-amino acids and β -alanine. Alternatively, when the modifying group is attached to the
25 carboxy-terminal end of the aggregation core domain, the amino-terminal end of the compound can be further modified, for example, to reduce the ability of the compound to act as a substrate for aminopeptidases.

30 A CXCR4 antagonist compound can be further modified to label the compound by reacting the compound with a detectable substance. Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials. Examples of suitable

WO 00/09152

PCT/CA99/00750.

enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; and examples of suitable radioactive material include ^{14}C , ^{123}I , ^{124}I , ^{125}I , ^{131}I , $^{99\text{m}}\text{Tc}$, ^{35}S or ^3H . In a preferred embodiment, a CXCR4 antagonist compound is radioactively labeled with ^{14}C , either by incorporation of ^{14}C into the modifying group or one or more amino acid structures in the CXCR4 antagonist compound. Labeled CXCR4 antagonist compounds can be used to assess the in vivo pharmacokinetics of the compounds, as well as to detect disease progression or propensity of a subject to develop a disease, for example for diagnostic purposes. Tissue distribution CXCR4 receptors can be detected using a labeled CXCR4 antagonist compound either in vivo or in an in vitro sample derived from a subject.

For use as an in vivo diagnostic agent, a CXCR4 antagonist compound of the invention may be labeled with radioactive technetium or iodine. A modifying group can be chosen that provides a site at which a chelation group for the label can be introduced, such as the Aic derivative of cholic acid, which has a free amino group. In another embodiment, the invention provides a CXCR4 antagonist compound labeled with radioactive iodine. For example, a phenylalanine residue within the SDF-1 sequence (such as aminoacid residue 13) can be substituted with radioactive iodotyrosyl. Any of the various isotopes of radioactive iodine can be incorporated to create a diagnostic agent. Preferably, ^{123}I (half-life=13.2 hours) is used for whole body scintigraphy, ^{124}I (half life=4

days) is used for positron emission tomography (PET), ¹²⁵I (half life=60 days) is used for metabolic turnover studies and ¹³¹I (half life=8 days) is used for whole body counting and delayed low resolution imaging studies.

5

An additional modification of a CXCR4 antagonist compound of the invention may serve to confer an additional therapeutic property on the compound. That is, the additional chemical modification can comprise an additional functional moiety. For example, a functional moiety which serves to cause apoptosis of tumour cells, can be coupled to the CXCR4 antagonist compound. In this form, the SDF-1 derived portion of the CXCR4 antagonist may serve to target the compound to the tumour and inhibit angiogenesis, whereas the additional functional moiety serves to cause apoptosis of the cancerous cells after the compound has been targeted to these sites.

In an alternative chemical modification, a compound of the invention is prepared in a "prodrug" form, wherein the compound itself does not modulate gamma interferon production or angiogenesis of a tumour, but rather is capable of being transformed, upon metabolism in vivo, into a CXCR4 antagonist compound as defined herein. For example, in this type of compound, the modulating group can be present in a prodrug form that is capable of being converted upon metabolism into the form of an active CXCR4 antagonist. Such a prodrug form of a modifying group is referred to herein as a "secondary modifying group." A variety of strategies are known in the art for preparing peptide prodrugs that limit metabolism in order to optimize delivery of the active form of the peptide-based drug (see e.g., Moss, J. (1995) in Peptide-Based Drug Design: Controlling Transport and Metabolism, Taylor, M. D. and Amidon, G. L. (eds), Chapter 18.

CXCR4 antagonist compounds of the invention can be prepared by standard techniques known in the art. The peptide component of a CXCR4 antagonist is composed, at least in part, of a peptide, which can be synthesized using standard techniques such as those described in Bodansky, M. Principles of Peptide Synthesis, Springer Verlag, Berlin (1993) and Grant, G. A. (ed.). Synthetic Peptides: A User's Guide, W. H. Freeman and Company, New York (1992). Automated peptide synthesizers are commercially available (e.g., Advanced ChemTech Model 396; Milligen/Bioscience 9600). Additionally, one or more modulating groups can be attached to the SDF-1 derived peptidic component by standard methods, for example using methods for reaction through an amino group (e.g., the alpha-amino group at the amino-terminus of a peptide), a carboxyl group (e.g., at the carboxy terminus of a peptide), a hydroxyl group (e.g., on a tyrosine, serine or threonine residue) or other suitable reactive group on an amino acid side chain (see e.g., Greene, T. W. and Wuts, P. G. M. Protective Groups in Organic Synthesis, John Wiley and Sons, Inc., New York (1991)). Exemplary syntheses of preferred CXCR4 antagonists is described further in the Examples.

Peptides of the invention may be chemically synthesized using standard techniques such as those described in Bodansky, M. Principles of Peptide Synthesis, Springer Verlag, Berlin (1993) and Grant, G. A. (ed.). Synthetic Peptides: A User's Guide, W. H. Freeman and Company, New York (1992) (all of which are incorporated herein by reference). Automated peptide synthesizers are commercially available (e.g., Advanced ChemTech Model 396; Milligen/Bioscience 9600).

In another aspect of the invention, peptides may be prepared according to standard recombinant DNA techniques using a nucleic acid molecule encoding the peptide. A

WO 00/09152

PCT/CA99/00750

nucleotide sequence encoding the peptide can be determined using the genetic code and an oligonucleotide molecule having this nucleotide sequence can be synthesized by standard DNA synthesis methods (e.g., using an automated DNA synthesizer).

- 5 Alternatively, a DNA molecule encoding a peptide compound can be derived from the natural precursor protein gene or cDNA (e.g., using the polymerase chain reaction (PCR) and/or restriction enzyme digestion) according to standard molecular biology techniques.

10

- The invention also provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a peptide of the invention. In some embodiments, the peptide may comprise an amino acid sequence having at least one amino acid
15 deletion compared to native SDF-1. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules and RNA molecules and may be single-stranded or double-stranded. In alternative embodiments, the isolated nucleic acid encodes a peptide wherein one or more amino acids are
20 deleted from the N-terminus, C-terminus and/or an internal site of SDF-1. In yet other embodiments, the isolated nucleic acid encodes a peptide fragment having one or more amino acids deleted compared to native SDF-1.

- 25 To facilitate expression of a peptide compound in a host cell by standard recombinant DNA techniques, the isolated nucleic acid encoding the peptide may be incorporated into a recombinant expression vector. Accordingly, the invention also provides recombinant expression vectors comprising the nucleic
30 acid molecules of the invention. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a plasmid, which refers to a circular double stranded DNA loop into which additional DNA segments
35 may be ligated. Another type of vector is a viral vector,

WO 00/09152

PCT/CA99/00750

wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal
5 mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to
10 which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" or simply "expression vectors".

In recombinant expression vectors of the invention, the
15 nucleotide sequence encoding a peptide may be operatively linked to one or more regulatory sequences, selected on the basis of the host cells to be used for expression. The terms "operatively linked" or "operably" linked mean that the sequences encoding the peptide are linked to the regulatory
20 sequence(s) in a manner that allows for expression of the peptide compound. The term "regulatory sequence" includes promoters, enhancers, polyadenylation signals and other expression control elements. Such regulatory sequences are described, for example, in Goeddel; Gene Expression
25 Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) (incorporated herein by reference). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell, those that direct expression of the nucleotide sequence
30 only in certain host cells (e.g., tissue-specific regulatory sequences) and those that direct expression in a regulatable manner (e.g., only in the presence of an inducing agent). It will be appreciated by those skilled in the art that the design of the expression vector may depend on such factors as
35 the choice of the host cell to be transformed, the level of

WO 00/09152

PCT/CA99/00750

expression of peptide compound desired, etc. The expression vectors of the invention can be introduced into host cells thereby to produce peptide compounds encoded by nucleic acids as described herein.

5

The recombinant expression vectors of the invention can be designed for expression of peptide compounds in prokaryotic or eukaryotic cells. For example, peptide compounds can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector may be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari et al., (1987) *EMBO J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz et al., (1987) *Gene* 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, Calif.). Baculovirus vectors available for expression of proteins or peptides in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al., (1983) *Mol. Cell. Biol.* 3:2156-2165) and the pVL series (Lucklow, V. A., and Summers, M. D., (1989) *Virology* 170:31-39). Examples of mammalian expression vectors include pCDM8 (Seed, B., (1987) *Nature* 329:840) and pMT2PC (Kaufman et al. (1987), *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40.

In addition to the regulatory control sequences discussed above, the recombinant expression vector may contain

WO 00/09152

PCT/CA99/00750

additional nucleotide sequences. For example, the recombinant expression vector may encode a selectable marker gene to identify host cells that have incorporated the vector. Such selectable marker genes are well known in the art. Moreover, 5 the facilitate secretion of the peptide compound from a host cell, in particular mammalian host cells, the recombinant expression vector preferably encodes a signal sequence operatively linked to sequences encoding the amino-terminus of the peptide compound such that upon expression, the peptide 10 compound is synthesised with the signal sequence fused to its amino terminus. This signal sequence directs the peptide compound into the secretory pathway of the cell and is then cleaved, allowing for release of the mature peptide compound (i.e., the peptide compound without the signal sequence) from 15 the host cell. Use of a signal sequence to facilitate secretion of proteins or peptides from mammalian host cells is well known in the art.

A recombinant expression vector comprising a nucleic acid 20 encoding a peptide compound that either inhibits gamma interferon production or inhibits angiogenesis can be introduced into a host cell to thereby produce the peptide compound in the host cell. Accordingly, the invention also provides host cells containing the recombinant expression 25 vectors of the invention. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding 30 generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein. A host cell may be any prokaryotic or eukaryotic cell. For example, a peptide compound may be 35 expressed in bacterial cells such as E. coli, insect cells,

WO 00/09152

PCT/CA99/00750

yeast or mammalian cells. Preferably, the peptide compound is expressed in mammalian cells. In a preferred embodiment, the peptide compound is expressed in mammalian cells in vivo in a mammalian subject to treat osis in the subject through gene therapy (discussed further below). Preferably, the peptide compound encoded by the recombinant expression vector is secreted from the host cell upon being expressed in the host cell.

10 Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign
15 nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, microinjection and viral-mediated transfection. Suitable methods for transforming or transfecting host cells can be
20 found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory manuals. Methods for introducing DNA into mammalian cells in vivo are also known in the art and can be used to deliver the vector DNA to a subject for gene
25 therapy purposes (discussed further below).

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate
30 the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those that
35 confer resistance to drugs, such as G418, hygromycin and

WO 00/09152

PCT/CA99/00750

methotrexate. Nucleic acid encoding a selectable marker may be introduced into a host cell on the same vector as that encoding the peptide compound or may be introduced on a separate vector. Cells stably transfected with the introduced
5 nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

A nucleic acid of the invention can be delivered to cells
10 in vivo using methods known in the art, such as direct injection of DNA, receptor-mediated DNA uptake or viral-mediated transfection. Direct injection has been used to introduce naked DNA into cells in vivo (see e.g., Acsadi et al. (1991) Nature 332:815-818; Wolff et al. (1990) Science
15 247:1465-1468). A delivery apparatus (e.g., a "gene gun") for injecting DNA into cells in vivo can be used. Such an apparatus is commercially available (e.g., from BioRad). Naked DNA can also be introduced into cells by complexing the DNA to a cation, such as polylysine, which is coupled to a ligand for
20 a cell-surface receptor (see for example Wu, G. and Wu, C. H. (1988) J. Biol. Chem. 263:14621; Wilson et al. (1992) J. Biol. Chem. 267:963-967; and U.S. Pat. No. 5,166,320). Binding of the DNA-ligand complex to the receptor facilitates uptake of the DNA by receptor-mediated endocytosis. Additionally, a DNA-
25 ligand complex linked to adenovirus capsids which naturally disrupt endosomes, thereby releasing material into the cytoplasm can be used to avoid degradation of the complex by intracellular lysosomes (see for example Curiel et al. (1991) Proc. Natl. Acad. Sci. USA 88:8850; Cristiano et al. (1993)
30 Proc. Natl. Acad. Sci. USA 90:2122-2126).

Defective retroviruses are well characterized for use in gene transfer for gene therapy purposes (for a review see Miller, A. D. (1990) Blood 76:271). Protocols for producing
35 recombinant retroviruses and for infecting cells in vitro or

in vivo with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F. M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Examples of suitable packaging virus lines include .psi.Crip, .psi.Cre, .psi.2 and .psi.Am. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, in vitro and/or in vivo (see for example Eglitis, et al. (1985) Science 230:1395-1398; Danos and Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464; Wilson et al. (1988) Proc. Natl. Acad. Sci. USA 85:3014-3018; Armentano et al. (1990) Proc. Natl. Acad. Sci. USA 87:6141-6145; Huber et al. (1991) Proc. Natl. Acad. Sci. USA 88:8039-8043; Ferry et al. (1991) Proc. Natl. Acad. Sci. USA 88:8377-8381; Chowdhury et al. (1991) Science 254:1802-1805; van Beusechem et al. (1992) Proc. Natl. Acad. Sci. USA 89:7640-7644; Kay et al. (1992) Human Gene Therapy 3:641-647; Dai et al. (1992) Proc. Natl. Acad. Sci. USA 89:10892-10895; Hwu et al. (1993) J. Immunol. 150:4104-4115; U.S. Pat. No. 4,868,116; U.S. Pat. No. 4,980,286; PCT Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573).

Alternatively, the genome of an adenovirus can be manipulated such that it encodes and expresses a peptide compound of the invention, but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See for example Berkner et al. (1988) BioTechniques 6:616; Rosenfeld et al. (1991) Science 252:431-434; and Rosenfeld et al. (1992) Cell 68:143-155. Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other

strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are well known to those skilled in the art. Recombinant adenoviruses are advantageous in that they do not require dividing cells to be effective gene delivery vehicles and can be used to infect
5 a wide variety of cell types, including airway epithelium (Rosenfeld et al. (1992) cited supra), endothelial cells (Lemarchand et al. (1992) Proc. Natl. Acad. Sci. USA 89:6482-6486), hepatocytes (Herz and Gerard (1993) Proc. Natl. Acad. Sci. USA 90:2812-2816) and muscle cells (Quantin et al. (1992)
10 Proc. Natl. Acad. Sci. USA 89:2581-2584).

Adeno-associated virus (AAV) can also be used for delivery of DNA for gene therapy purposes. AAV is a naturally occurring defective virus that requires another virus, such as
15 an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. (For a review see Muzyczka et al. Curr. Topics in Micro. and Immunol. (1992) 158:97-129). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high
20 frequency of stable integration (see for example Flotte et al. (1992) Am. J. Respir. Cell. Mol. Biol. 7:349-356; Samulski et al. (1989) J. Virol. 63:3822-3828; and McLaughlin et al. (1989) J. Virol. 62:1963-1973). An AAV vector such as that described in Tratschin et al. (1985) Mol. Cell. Biol. 5:3251-
25 3260 can be used to introduce DNA into cells. A variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example Hermonat et al. (1984) Proc. Natl. Acad. Sci. USA 81:6466-6470; Tratschin et al. (1985) Mol. Cell. Biol. 4:2072-2081; Wondisford et al. (1988)
30 Mol. Endocrinol. 2:32-39; Tratschin et al. (1984) J. Virol. 51:611-619; and Flotte et al. (1993) J. Biol. Chem. 268:3781-3790).

In another embodiment, the invention provides a method
35 for treating a subject suffering from cancer or an autoimmune

WO 00/09152

PCT/CA99/00750.

disease (e.g. multiple sclerosis), comprising administering to the subject a recombinant expression vector encoding an SDF-1 derived peptide compound such that the peptide compound is synthesised in the subject and the subject is treated for a disorder associated with cancer or an autoimmune disease. The peptide compound may comprise a peptide fragment having at least one amino acid deletion compared to native SDF-1.

A further application of CXCR4 antagonists may also be in the field of cancer therapy. Since the growth of solid tumors is angiogenesis-dependent, and the endothelial cells (essential for the blood vessels formation) carry the SDF-1 receptor, it is possible that SDF-1-derived antagonists may inhibit tumor growth by their anti-angiogenesis effect.

General methods for gene therapy are known in the art. See for example, U.S. Pat. No. 5,399,346 by Anderson et al. A biocompatible capsule for delivering genetic material is described in PCT Publication WO 95/05452 by Baetge et al. Methods for grafting genetically modified cells to treat central nervous system disorders are described in U.S. Pat. No. 5,082,670 and in PCT Publications WO 90/06757 and WO 93/10234, all by Gage et al.

Furthermore, alternative to expression of an SDF-1 derived peptide to inhibit gamma interferon production or inhibit angiogenesis, an antisense oligonucleotide that is complementary to a region of the SDF-1 precursor protein mRNA corresponding to the peptides described herein can be expressed in a subject to inhibit gamma interferon production or inhibit angiogenesis. General methods for expressing antisense oligonucleotides to modulate nervous system disorders are described in PCT Publication WO 95/09236.

Peptides may be prepared in accordance with standard

methods (such as disclosed in Clark-Lewis, I., Dewald, B., Loetscher, M., Moser, B., and Baggiolini, M., (1994) J. Biol. Chem., 269, 16075-16081) and assayed for CXCR4 antagonist activity in accordance with standard methods.

- 5 Peptides may be purified by HPLC and analyzed by mass spectrometry. Peptides may be dimerized via a disulfide bridge formed by gentle oxidation of the cysteines using 10% DMSO in water. Following HPLC purification dimer formation may be verified, by mass spectrometry.

10

- For CXCR4 antagonist assays, human peripheral blood mononuclear cells may be isolated using standard methods, such as from donor blood buffy coats by centrifugation on Ficoll-Paque. The cells may be treated with phytohemagglutinin (1.0 $\mu\text{g}.\text{ml}^{-1}$) and expanded in the presence of IL-2 (100U. ml^{-1}) for 15 7 to 17 days as described (Loetscher, P., Seitz, M., Clark-Lewis, I., Baggiolini, M., and Moser, B., (1994) FASEB J., 8, 1055-1060). These cells may be used as the "T-lymphocytes" for various assays of CXCR4 receptor activity. CEM cells, a 20 human lymphoblastoid CD4⁺T cell line (ATCC, Rockville MD), may be cultured in RPMI medium containing 15 $\mu\text{g}.\text{ml}^{-1}$ of 8-azaguanine (Aldrich Chemical Company, Milwaukee WI) and 10% FCS.

- 25 Migration of T-lymphocytes or CEM cells may be assessed in accordance with standard methods. Such methods may utilize 48 well chambers (NeuroProbe, Cabin John MD) using collagen-coated polyvinylpyrrolidone-free polycarbonate membranes with 3 μm pores (Loetscher, P., Seitz, M., Clark-Lewis, I., Baggiolini, M., and Moser, B., (1994) FASEB J., 30 8, 1055-1060). Migrated cells may be counted in five randomly selected fields at 1000x magnification after migration of 1h. Disposable Transwell trays (Colstar, Cambridge MA) with 6.5 mm diameter chambers and membrane

- pore size of 3 μm , may be used to assay chemotaxis of CEM cells. The putative antagonist, in Hepes-buffered RPMI 1640 supplemented with 10 $\text{mg}\cdot\text{ml}^{-1}$ BSA (0.6Ml), may be added to the lower well, and 0.1 ml of CEM cells ($1\times 10^7\cdot\text{ml}^{-1}$) in the same medium without agonist was added to the upper wells. The monoclonal antibody 12G5 (von Tscharner, V., Prod'homme, B., Baggiolini, M., and Reuter, H., (1986) *Nature*, 324, 369-372; R&D Systems, Minneapolis MN) may be preincubated with the cells at 10 $\mu\text{g}\cdot\text{ml}^{-1}$ for 15 min at 0°C .
- The antibody may also be added to the lower well at 10 $\mu\text{g}\cdot\text{ml}^{-1}$. After 2 h, cells that migrated to the lower wells may be counted. Chemotactic migration may be determined by subtraction of cells migrated in medium alone.
- The sequences of various peptides assayed for their activity on CXCR4 are shown in Figure 1. Both the SDF(1-8) and SDF(1-9) peptides induced dose-dependent chemotaxis of CEM cells (Figure 2a). the concentrations required for 50% of the maximal response (EC50) are summarized in Table 1.
- The 1-9 peptide was about 1,000-fold less potent than native SDF-1. However the 1-9 was 7-fold more potent than the 1-8 peptide. the peptides were also tested on T-lymphocytes (Figure 2b) and the results were similar to those obtained with CEM cells, except that the T-lymphocytes were less responsive to SDF-1 or the peptides. The chemoattractant activity of SDF-1(1-9) was fully inhibited by the SDF-1 antagonist, SDF-1(1-67) [P2G] (Crump, M., Gong J.-H., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana-Seisdedos, F., Virelizier, J.-L., Baggiolini, M., Sykes, B.D., and Clark-Lewis, I., (1997) *EMBO J.*, 16, 6996-7007), but not by an IL-8 antagonist which blocks CXCR1 (Crump, M., Gong J.-H., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana-Seisdedos, F., Virelizier, J.-L., Baggiolini, M., Sykes, B.D., and Clark-Lewis, I., (1997) *EMBO J.*, 16, 6996-

7007) (Figure 3).

To investigate the effect of increasing the peptide length to include both the N-terminal CXC motif and RFFESH binding domains, we prepared SDF-1(1-17). This peptide was more potent than 1-9 but was several fold lower in chemotactic activity than 1-9 dimer (Figure 2a). Dimerization of 1-17 did not affect its potency (not shown). This suggests that a SDF-1(1-17) peptide in which there is a P2G substitution would be an active CXCR4 antagonist.

Competition for binding of 125 I-labelled SDF-1 to CEM cells may be carried out as described (Crump, M., Gong J.-H., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana-Seisdedos, F., Virelizier, J.-L., Baggiolini, M., Sykes, B.D., and Clark-Lewis, I., (1997) EMBO J., 16, 6996-7007). MCP-1 and RANTES binding may be measured to THP-1 cells (Gong, J.-H., Uguccioni, M., Dewald, B., Baggiolini, M., and Clark-Lewis, I., (1996) J. Biol. Chem., 271, 10521-10527).

20

CEM cells may be used to determine the binding of the SDF-1 peptide to CXCR4 (Crump, M., Gong J.-H., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana-Seisdedos, F., Virelizier, J.-L., Baggiolini, M., Sykes, B.D., and Clark-Lewis, I., (1997) EMBO J., 16, 6996-7007). For example, the competition for binding of 125 I-labelled native SDF-1 by unlabelled native SDF-1 and the N-terminal peptides is shown in Figure 4. The K_d values are summarized in Table 1. To determine whether peptides bind to other chemokine receptors, competition for MCP-1 or RANTES binding to THP-1 cells may be measured. THP-1 cells express CXCR4 as well as a number of CC chemokine receptors, including receptors for MCP-1 and RANTES.

T-lymphocytes and CEM cells loaded with Fura-2 may be stimulated with the putative antagonist, and the

WO 00/09152

PCT/CA99/00750.

[Ca²⁺]_i-related fluorescence changes recorded from 0-60 s (Jones, S.A., Dewald, B., Clark-Lewis, I., and Baggiolini, M., (1997) J. Biol. Chem., 272, 16166-16169). Receptor desensitization may be tested by monitoring changes
5 during sequential additions at 60 s intervals. Cells may be preincubated with the 12G5 antibody prior to chemokine treatment.

CXCR4 agonists, such as native SDF-1 and the N-terminal
10 peptides, induce a rapid and transient rise in cytoplasmic concentration, [Ca²⁺]_i, in T-lymphocytes (Figure 5a) as well as CEM cells (Figure 6). The rate and magnitude may increase with the concentration. Whereas a response to SDF-1 was observed at 1 x 10⁻⁹ M, the peptides induced [Ca²⁺]_i changes in
15 the micromolar range. Receptor usage by SDF-1 derived peptides may be assessed by monitoring [Ca²⁺]_i changes after sequential stimulation. As shown in Figure 5a, treatment of T-lymphocytes with SDF-1 completely abolished the responsiveness to the 1-9 peptide, and conversely, the 1-9
20 peptide also markedly attenuated the response to native SDF-1. The 1-9 dimer (50 μM) completely desensitized the response to subsequent native SDF-1 (not shown). No effect on the response to the 1-9 peptide was observed when T-lymphocytes were pre-stimulated with MCP-1, RANTES, MIP-1β, IP10, or Mig
25 (Figure 5b). No response to eotaxin, 1-309 or TARC (Figure 5b) was obtained with these cells under the conditions used, and as expected, they did not desensitize 1-9.

Peptides may be assayed for receptor binding using a
30 CXCR4 blocking monoclonal antibody (von Tscharner, V., Prod'homme, B., Baggiolini, M., and Reuter, H., (1986) Nature, 324, 369-372).

WO 00/09152

PCT/CA99/00750..

Competative binding assays have shown similar levels of CXCR4 binding by a variety of SDF-1 derived peptide dimers, including SDF-1(1-8), and SDF-1(1-9), dimers where the linking group differs in length, being either lysine, ornithine or L-amino-N-butyric acid.

Example 1

This example shows the inhibitory effects of CXCR4 antagonists on tumor growth using mouse models.

10

Two CXCR4 antagonists used were: (i) the full length SDF-1 antagonist, SDF-1(1-67)[P2G]; and (ii) the short peptide dimer antagonist, SDF-1(1-9[P2G]),. Two animal models used were: (i) the Lewis lung carcinoma on its syngeneic host, the C57BL/6 mice; and (ii) the line-1 carcinoma (a weakly antigenic, highly malignant metastasis model) on its syngeneic host, the BALB/c mice. Male mice, 1.5-3 months old were used.

15

Treatment protocols were as follows. On day 0, tumor cells ($1-2 \times 10^6$) were subcutaneously (SC) implanted on the back of each mouse. Treatment with the CXCR4 antagonists started immediately after the tumor implantation. The SDF-1(1-67)[P2G] (9 mg/kg/day) or the SDF(1-9[P2G]), dimer (18 mg/kg/day), dissolved in phosphate buffer, were intraperitoneally (ip), as indicated in the Figures. The injection was once a day for a total of 12-16 days. Tumor size was determined with micrometer and the volume of the tumor was calculated by the form of width² x length. Tumor mass was determined at the end of each experiment.

20
25
30

Both the full length (SDF-1 P2G) and the short peptide SDF-1 derived CXCR4 antagonists inhibited the line-1 and Lewis lung carcinoma growth. When compared to the day 12 controls, the SDF-1(1-67)[P2G] inhibited the line-1 lung carcinoma

WO 00/09152

PCT/CA99/00750

growth by >80%, at a dose of 9 mg/kg (Figure 6) or 64%, at a dose of 4 mg/kg (Figure 7). For Lewis lung carcinoma, at day 12, the SDF-1(1-67)[P2G] inhibited the tumor growth by 45%, at a dose of 4 mg/kg (Figure 9). Subcutaneous injection also
5 inhibited tumor growth, however, the efficiency was less than that of ip. Injection.

The degree of tumor growth inhibition by CXCR4 inhibitors correlated with the compounds degree of CXCR4 antagonist
10 activity. The SDF(1-9)P2G dimer was generally a less potent inhibitor of tumor growth than the full length SDF-1(1-67)[P2G] analogue. This indicates that it is the antagonistic activity of these compounds that mediates their chemotherapeutic effect. Nevertheless, even the SDF(1-9)P2G
15 dimer exhibited significant tumor growth inhibiting activity. At a dose of 18 mg/kg The SDF(1-9)P2G dimer inhibited the growth of the Line-1 tumor by 35% at day 12, and inhibited the growth of the Lewis lung carcinoma by 43% at day 12. Tumor mass generally correlated to that of the tumor size
20 determination (Figure 8 & 10).

Histological studies show that the tumors from the CXCR4 antagonist treated mice had a lower density of blood vessels than tumors in the control mice, indicating that SDF-1
25 antagonists act as an angiogenesis inhibitors to reduce neovascularization of tumors.

In the mouse models, no toxicity of CXCR4 antagonists was detected during treatment up to the dose of 18 mg/kg.

30

Example 2

This example shows the inhibition by CXCR4 inhibitors of interferon-gamma production by activated T-cells.

WO 00/09152

PCT/CA99/00750

T-cells were isolated and cultured using standard methods as follows. Human blood was taken by venipuncture from healthy donors. Blood was drawn into an anti-coagulant solution (ACD), mixed with an equal volume of saline solution and layered over Histopaque. Following centrifugation (1200 rpm, 30 minutes), the upper plasma solution was discarded and cells at the interface between the solutions were collected. Cells were washed twice by resuspending in Tyrode's buffer and centrifugation to pellet the cells. The final cell pellet was resuspended in RPMI 1640 containing antibiotics and 20% fetal bovine serum. Cells were plated into tissue culture flasks for 2 hours to allow adherent cells to attach. The non-adherent cells (enriched with T-lymphocytes) were counted using Trypan blue to detect viable cells. Cells were cultured at an initial concentration of 1×10^6 per ml for 48 hours at 37°C in a humidified incubator with 5% CO₂, 95% air. Additions of Concanavalin A at 1 µg/ml, 1000 Units/ml of interferon-beta, and/or peptides at various concentrations were made at the 0 time point. To assay for interferon-gamma production, the cell suspension was centrifuged to pellet cells and the supernatant was assayed using a commercial ELISA assay kit (Pharmingen).

Table 2 shows interferon-gamma produced by T-cells in culture following stimulation with 1µg/ml Concanavalin A (Con. A) in the presence of various concentrations of SDF-1 (i.e., 0, 2.5, 5, 7.5 or 10 nM). In these studies, cells treated with interferon beta did not generate more interferon gamma in response to SDF-1. However, significant decrease in the production of interferon gamma was seen when the cells were stimulated with interferon beta synergistically with SDF-1(1-67) [P2G].

Table 1: Gamma Interferon Production (pg/ml gamma interferon)

		SDF-1 Concentration (nM)				
		0	2.5	5	7.5	10
5	Control (Con.A)	3,900	4,850	5,700	5,750	5,760
10	Beta Interferon treated	3,800	2,600	3,700	3,700	3,800

Table 1 demonstrates that the level of interferon gamma released from T-cells in cultures in response to stimulation with Concanavalin A is almost 4,000 pg/ml, and this is reduced by treatment with interferon beta. Treatment of T-cells with SDF-1 at the same time as Concanavalin A enhances the production of interferon gamma. There is no effect of SDF-1 addition in reversing the effect of interferon beta.

In contrast, SDF-1 derived CXCR4 antagonists have a significant effect on the production of gamma interferon from the T-cells. This is demonstrated by experiments similar to the studies with interferon beta. Human lymphocytes were exposed to various concentrations of SDF-1 antagonist (SDF-1-P2G and then the cells were activated with Concanavalin A (Con. A). Production of interferon gamma from T-cells exposed to SDF-1 antagonist was measured and compared to the amount released from T-cells that were not treated with the antagonist.

Table 2 demonstrates the effect of a CXCR4 antagonist (SDF-1(1-67) [P2G]) on the release of gamma interferon from T-cells activated by Concanavalin A (Con. A), in the presence and in the absence (control) of beta interferon treatment.

Table 2: SDF-1(1-67)[P2G] Concentration (nM)

		0	2.5	5	10
5	Control	3,900	3,700	3,400	3,600
	Beta Interferon Treatment	3,500	2,100	1,800	2,400

10

The data in Table 2 demonstrates that a CXCR4 antagonist can diminish the release of interferon gamma by the T-cells. Furthermore, when the SDF-1 antagonist is added together with the interferon beta, there is an even greater effect on the reduction on interferon gamma production. Accordingly, a CXCR4 antagonist may be used together with interferon beta to reduce gamma interferon production by activated T-cells, for example T-cells that have been physiologically activated in a patient. For example, CXCR4 antagonists may be used with interferon beta in the treatment of patients with MS.

Table 3 shows the different effects of a CXCR4 agonist (SDF-1) and a CXCR4 antagonist (SDF-1(1-67)[P2G]), when each is used with interferon beta, on the production of interferon gamma from the Con. A activated T-cells. For comparison, Table 4 also shows data for interferon beta alone.

WO 00/09152

PCT/CA99/00750

**Table 3: Effect of 10 nM SDF-1
and SDF-1(1-67)[P2G] (Antagonist) on the Production
of Interferon Gamma from Human T-cells**

5		Interferon gamma (pg/ml)
	Control (Con. A)	3,950
10	Interferon beta	3,500
	SDF-1 + Interferon beta	3,500
	Antagonist (SDF-1-P2G) + Interferon beta	1,300

15

The CXCR4 antagonist (SDF-1(1-67)[P2G]) is able to synergistically potentiate the effect of interferon beta in down regulating the production of interferon gamma from activated T-cells. Addition of interferon beta by itself had a small effect on the reduction of interferon gamma release from T-cells. The SDF-1 treatment does not change the effect of interferon beta, but the SDF-1 antagonist (SDF-1-P2G) causes a dramatic reduction in interferon-gamma production.

25

Table 4 shows the different effects of a CXCR4 antagonist (SDF-1(1-67)[P2G]) on the release of gamma interferon from T-cells activated by concanavalin A (Con.A) in the absence of beta interferon.

30

**Table 4: Effect of 0.1 μ M and 1 μ M SDF-1(1-67)[P2G]
on the Production of Interferon Gamma
from Human T-cells**

35		Interferon gamma (pg/ml)
	Control (unstimulated)	80
	Con. A (activated)	2,200
	Con. A + SDF-1(1-67)[P2G] (0.1 μ M)	1,050
40	Con. A + SDF-1(1-67)[P2G] (1 μ M)	1,100

The data in Table 4 demonstrates that a CXCR4 antagonist can diminish the release of interferon gamma by T-cells. Accordingly, a CXCR4 antagonist may be used to reduce interferon gamma production by activated T-cells, for example, T-cells that have been physiologically activated in a patient suffering from multiple sclerosis.

Table 5 shows the different effects of a CXCR4 antagonist (SDF-1(1-9)P2G) on the release of gamma interferon from T-cells activated by concanavalin A (Con.A) in the absence of beta interferon.

Table 5: Effect of 1 μ M and 10 μ M SDF-1(1-9)[P2G] on the Production of Interferon Gamma from Human T-cells

	Interferon gamma (pg/ml)
Control (unstimulated)	100
Con. A (activated)	2,200
Con. A + SDF-1(1-9)[P2G] (1 μ M)	1,100
Con. A + SDF-1(1-9)[P2G] (10 μ M)	1,000

The data in Table 5 further demonstrates that a shortened peptide CXCR4 antagonist can diminish the release of interferon gamma by T-cells. Accordingly, a CXCR4 antagonist of a shorter length may be used to reduce interferon gamma production by activated T-cells.

Figures 15, 17, 19, 21 and 23 show the effect of various SDF-1 derived peptides on interferon gamma (IFN-g) release from Con. A activated (stimulated) mixed human lymphocytes. Similarly, Figures 16, 18, 20, 22 and 24 show the effect of various SDF-1 derived peptides on tumor necrosis factor alpha (TNF-a) release by Con. A activated (stimulated) mixed human lymphocytes. The results demonstrate that a number of these

WO 00/09152

PCT/CA99/00750

SDF-1 derived peptides inhibit the release of IFN-g and TNF-a from human cells in vitro.

The SDF-1 derived peptide SDF-1(1-9[P2G]), has also been shown to inhibit the development of MS in an established animal model of MS, experimental autoimmune encephalomyelitis (EAE) in mice. In these experiments, mice received myelin basic protein (MBP) and *Bordetella* bacterium to induce EAE. The effects of SDF-1(1-9[P2G]), on the development of paralysis in mice were then studied. The mice were divided into two groups that received either a daily dose of SDF-1(1-9[P2G]), (5 mg/kg i.p.) for 10 days, or no treatment (the control group). Mice were routinely observed for signs of paralysis or other physiological changes and graded as follows: 1) floppy tail; 2) hindlimb paralysis; 3) paraplegia; 4) forelimb paralysis; 5) morbidity -like. All the control animals developed paralysis (grade 2-3) after 7-10 days post MBP injection. One animal became severely paralyzed (grade 3-4) after 5 days and died after 7 days. The remaining control animals showed signs of paralysis (grade 2-3) after 8-12 days and reached grade 4 by day 15. At day 17, 75% of control animals developed grade 5. In contrast, SDF-1(1-9[P2G]), treated animals showed only slight signs of paralysis. By day 10, 50% of SDF-1(1-9[P2G]), treated animals developed grade 2-3, however they had recovered by day 15. By day 17, all the SDF-1(1-9[P2G]), treated animals showed no signs of paralysis. These results indicate that SDF-1(1-9[P2G]), not only reduced the rate of onset and progress of paralysis, but was able to reverse the paralysis. These results are illustrated in Figure 25.

WO 00/09152

PCT/CA99/00750

What is claimed is:

1. The use of a CXCR4 antagonist for the manufacture of a medicament for reducing interferon gamma production by T-cells in a mammal.
2. The use of a CXCR4 antagonist for reducing interferon gamma production by T-cells in a mammal.
3. The use of a CXCR4 antagonist for the manufacture of a medicament for the treatment of an autoimmune disease in a mammal.
4. The use of a CXCR4 antagonist for the treatment of an autoimmune disease in a mammal.
5. The use of a CXCR4 antagonist for the manufacture of a medicament for the treatment of multiple sclerosis in a mammal.
6. The use of a CXCR4 antagonist for the treatment of multiple sclerosis in a mammal.
7. The use of a CXCR4 antagonist according to claim 5, wherein the medicament comprises beta interferon.
8. The use of a CXCR4 antagonist according to claim 5, 6 or 7 wherein the mammal is undergoing treatment with beta interferon.
9. The use of a CXCR4 antagonist for the manufacture of a medicament for the treatment of cancer in a mammal.
10. The use of a CXCR4 antagonist for the manufacture of a medicament for inhibiting angiogenesis in a mammal.

WO 00/09152

PCT/CA99/00750

11. The use of a CXCR4 antagonist for the manufacture of a medicament for the treatment of cancer by inhibiting angiogenesis in a mammal.
- 5 12. The use of a CXCR4 antagonist for the manufacture of a medicament.
- 10 13. The use of a CXCR4 antagonist according to any one of claims 1 through 12, wherein the CXCR4 antagonist is a peptide compound comprising a substantially purified peptide fragment, modified fragment, analog or pharmacologically acceptable salt of SDF-1.
- 15 14. The use of a CXCR4 antagonist according to claim 13, wherein the peptide compound comprises an N-terminal amino acid sequence KGVSLSYRC-R₁ (SEQ ID NO: 2) wherein R₁ is selected from the group consisting of hydrogen and polypeptides homologous to at least a portion of SDF-1.
- 20 15. The use of a CXCR4 antagonist according to any one of claims 1 through 14, wherein the mammal is a human.
- 25 16. A method of medical treatment comprising the use of a CXCR4 antagonist according to any one of claims 1 through 15, wherein the CXCR4 antagonist is administered to the mammal in a therapeutic dose in a pharmacologically acceptable formulation.
- 30 17. A therapeutic composition comprising a CXCR4 antagonist and a pharmacologically acceptable excipient.
18. The therapeutic composition of claim 17 further comprising interferon beta.
- 35 19. The use of a CXCR4 antagonist according to claim 13, wherein the peptide compound comprises a dimer of SEQ ID NO:3 according to the following formula:

WO 00/09152

PCT/CA99/00750

KGVSLSYR

|

X

|

5

KGVSLSYR

wherein X is lysine and both the α and ϵ amino groups of the lysine are associated with amide bond formation and the lysyl carboxyl group is protected.

- 10 20. The use of a CXCR4 antagonist according to claim 13, wherein the peptide compound comprises a dimer of SEQ ID NO:4 according to the following formula:

KGVSLSYRC

|

15

X

|

KGVSLSYRC

20

wherein X is lysine and both the α - and ϵ - amino groups of the lysine are associated with covalent bond formation to the adjacent cysteine amino acid residues.

21. A polymeric CXCR4 antagonist comprising a plurality of peptides covalently joined by a bridging moiety so that the polymeric CXCR4 antagonist has a plurality of N-terminals.

25

22. The polymeric CXCR4 antagonist according to claim 21, is SDF-1(1-9[P2G])₂.




Fig. 1

WO 00/09152

PCT/CA99/00750




Fig. 2

2/25

WO 00/09152

PCT/CA99/00750




Fig. 3

WO 00/09152

PCT/CA99/00750




Fig. 4

WO 00/09152

PCT/CA99/00750




Fig. 5

5/25

WO 00/09152

PCT/CA99/00750

Tumor Size (Line-1 Mouse Lung Carcinoma)
(Mean \pm SEM)
March 27, 1998




Fig. 6

6/25

WO 00/09152

PCT/CA99/00750

Inhibition of Lung Carcinoma (Line-1)-Growth*
by Full length SDF-1 Antagonist
Or by Short Peptide Antagonist
(May 15, 1998)




Fig. 7

7/25

WO 00/09152

PCT/CA99/00750





Fig. 8

8/25

WO 00/09152

PCT/CA99/00750

Inhibition of Mouse Lung Carcinoma*-Growth
By Full Length SDF-1 Antagonist
or by Short Antagonist
(July 18,1998)**



* Lung carcinoma: Lewis Lung carcinoma

** shown are the mean +/- SEM of the tumor size.

Fig. 9

9/25

WO 00/09152

PCT/CA99/00750

**Mass of Tumor (Lewis Lung Carcinoma) on Day 12
(July 18, 1998)**




Fig. 10

10/25

WO 00/09152

PCT/CA99/00750

**Effect of SDF-1 on ConA-stimulated
Interferon-gamma production in
Human T cells**




Fig. 11

11/25

WO 00/09152

PCT/CA99/00750

Effect of SDF-1 Antagonist on ConA-stimulated
Interferon-gamma production in
Human T cells




Fig. 12

12/25

WO 00/09152

PCT/CA99/00750




Fig. 13

WO 00/09152

PCT/CA99/00750




Fig. 14

WO 00/09152

PCT/CA99/00750

IFN-gamma Released from ConA(0.5ug/ml) Stimulated Mixed Cells
H.Salarl (12/07/99)




Fig. 15

15/25

WO 00/09152

PCT/CA99/00750

TNF- α Released from ConA(0.5ug/ml) Stimulated Mixed Cells
H.Salari (12/07/99)




Fig. 16

16/25

WO 00/09152

PCT/CA99/00750

IFN-gamma Released from ConA(0.5ug/ml) Stimulated Mixed Cells
H. Salari (12/07/99)




Fig. 17
17/25

WO 00/09152

PCT/CA99/00750

TNF- α Released from ConA(0.5ug/ml) Stimulated Mixed Cells
H.Salari (12/07/99)




Fig. 18

18/25

WO 00/09152

PCT/CA99/00750

IFN-gamma Released from ConA(0.5ug/ml) Stimulated Mixed Cells H.Salarl (12/07/99)




Fig. 19

19/25

WO 00/09152

PCT/CA99/00750


TNF- α Released from ConA(0.5ug/ml) Stimulated Mixed Cells H.Salari (12/07/99)

Fig. 20

20/25

WO 00/09152

PCT/CA99/00750

IFN-gamma Released from ConA(0.5ug/ml) Stimulated Mixed Cells

H. Salari (12/07/99)




Fig. 21

21/25

WO 00/09152

PCT/CA99/00750

H.Salari (12/07/99)

TNF- α Released from ConA(0.5ug/ml) Stimulated Mixed Cells




Fig. 22

22/25

WO 00/09152

PCT/CA99/00750

IFN-gamma Released from ConA(0.5ug/ml) Stimulated Mixed Cells H.Salari (12/07/99)




Fig. 23

23/25

WO 00/09152

PCT/CA99/00750

TNF- α Released from ConA(0.5ug/ml) Stimulated Mixed Cells H.Salari (12/07/99)




Fig. 24

24/25

WO 00/09152

PCT/CA99/00750




Fig. 25

WO 00/09152

PCT/CA99/00750

SEQUENCE LISTING

<110> CLARK-LEWIS, Ian
 GIONG, Jiang-Hong
 DURONIO, Vincent
 SALARI, Hassan
 The University of British Columbia

<120> Chemokine Receptor Antagonists

<130> 80021-41

<140>

<141>

<150> CA 2,245,224

<151> 1998-08-14

<160> 7

<170> PatentIn Ver. 2.0

<210> 1

<211> 17

<212> PRT

<213> Homo sapiens

<400> 1

Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
 1 5 10 15

His

<210> 2

<211> 9

<212> PRT

<213> Homo sapiens

<400> 2

Lys Gly Val Ser Leu Ser Tyr Arg Cys
 1 5

<210> 3

<211> 8

<212> PRT

<213> Homo sapiens

WO 00/09152

PCT/CA99/00750

<400> 3

Lys Gly Val Ser Leu S r Tyr Arg
1 5

<210> 4

<211> 9

<212> PRT

<213> Homo sapiens

<400> 4

Lys Gly Val Ser Leu Ser Tyr Arg Cys
1 5

<210> 5

<211> 6

<212> PRT

<213> Homo sapiens

<400> 5

Arg Phe Phe Glu Ser His
1 5

<210> 6

<211> 67

<212> PRT

<213> Homo sapiens

<400> 6

Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
1 5 10 15His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
20 25 30Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
35 40 45Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
50 55 60Ala Leu Asn
65

<210> 7

<211> 72

<212> PRT

<213> Homo sapiens

<400> 7

Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
1 5 10 15

His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro

WO 00/09152

PCT/CA99/00750

20	25	30
Asn Cys Ala Leu Gln Ile Val	Ala Arg Leu Lys Asn Asn Asn Arg Gln	
35	40	45
Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys		
50	55	60
Ala Leu Asn Lys Arg Phe Lys Met		
65	70	

INTERNATIONAL SEARCH REPORT -

International Application No

P. CA 99/00750

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/21 C07K14/52		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CRUMP M P ET AL: "SOLUTION STRUCTURE AND BASIS FOR FUNCTIONAL ACTIVITY OF STROMAL CELL-DERIVED FACTOR-1: DISSOCIATION OF CXCR4 ACTIVATION FROM BINDING AND INHIBITION OF HIV-1" EMBO JOURNAL, vol. 16, no. 23, 1997, pages 6996-7007, XP002915918 ISSN: 0261-4189 cited in the application the whole document	1-22
Y	WO 98 09642 A (OPPENHEIM JOOST J ;US GOVERNMENT (US); ARTHUR LARRY O (US); CHERTO) 12 March 1998 (1998-03-12) the whole document	1-8, 12-22
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		
<input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "Δ" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
18 November 1999		26/11/1999
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Hagenmaier, S

INTERNATIONAL SEARCH REPORT -

International Application No

P./CA 99/00750

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GUPTA ET AL.: "CHEMOKINE RECEPTORS IN HUMAN ENDOTHELIAL CELLS" J.BIOL.CHEM., vol. 273, no. 7, February 1998 (1998-02), pages 4282-4287, XP002115362 cited in the application the whole document ---	9-11
Y	DHIB-JALBUT S ET AL: "Comparative effects of Interferon - consensus 1, interferon -alpha 2a, and interferon -beta 1b on HLA expression and lymphoproliferation: a preclinical model for treatment of multiple sclerosis" JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, vol. 16, no. 3, 1 March 1996 (1996-03-01), pages 195-200, XP002081554 ISSN: 1079-9907 the whole document ---	1,2,7,8, 18
Y	CWIRLA S E ET AL: "PEPTIDE AGONIST OF THE THROMBOPOIETIN RECEPTOR AS POTENT AS THE NATURAL CYTOKINE" SCIENCE, vol. 276, 13 June 1997 (1997-06-13), pages 1696-1699, XP002067303 ISSN: 0036-8075 the whole document ---	19-22
Y	WO 96 40772 A (JOHNSON & JOHNSON ;JOHNSON DANA L (US); ZIVIN ROBERT A (US)) 19 December 1996 (1996-12-19) the whole document ---	19-22
Y	"INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS. CLINICAL RESULTS OF A MULTICENTER, RANDOMIZE, DOUBLE -BLIND, PLACEBO-CONTROLLED TRIAL" NEUROLOGY, vol. 43, no. 4, 1 April 1993 (1993-04-01), pages 655-661, XP000578355 ISSN: 0028-3878 the whole document ---	7,8,18
A	WO 98 04698 A (CLARK LEWIS IAN ; MOSER BERNHARD (CH); BAGGIOLINI MARCO (CH); ARENZ) 5 February 1998 (1998-02-05) cited in the application the whole document ---	

-/--

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 99/ 00750

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 2,4,6,8,13-16,19,20 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT -

International Application No

F./CA 99/00750

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
A	NAGASAWA ET AL.: "DEFECTS OF B-CELL LYMPHOPOIESIS AND BONE-MARROW MYELOPOIESIS IN MICE LACKING THE CXC CHEMOKINE PBSF/SDF-1" NATURE, vol. 382, 1996, pages 635-638, XP002115695 the whole document ----	
A	WO 97 28258 A (NAT INST HEALTH) 7 August 1997 (1997-08-07) cited in the application the whole document ----	
P,X	LOETSCHER ET AL.: "N-TERMINAL PEPTIDES OF STROMAL CELL-DERIVED FACTOR WITH CXC CHEMOKINE RECEPTOR 4 AGONIST AND ANTAGONIST ACTIVITIES" J.BIOL.CHEM., vol. 273, no. 35, 28 August 1998 (1998-08-28), pages 22279-22283, XP002115696 the whole document ----	12-17, 19-22
P,A	WO 98 51705 A (LUSSO PAOLO ;FONDAZIONE CENTRO SAN RAFFAELE (IT)) 19 November 1998 (1998-11-19) the whole document -----	

INTERNATIONAL SEARCH REPORT -

Information on patent family members

International Application No

P. /CA 99/00750

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9809642 A	12-03-1998	AU 4251197 A	26-03-1998
WO 9640772 A	19-12-1996	US 5767078 A	16-06-1998
		AU 6100796 A	30-12-1996
		CA 2228277 A	19-12-1996
		EP 0892812 A	27-01-1999
WO 9804698 A	05-02-1998	FR 2751658 A	30-01-1998
		AU 3854797 A	20-02-1998
		CA 2259948 A	05-02-1998
		EP 0917575 A	26-05-1999
WO 9728258 A	07-08-1997	AU 1834197 A	22-08-1997
		EP 0854918 A	29-07-1998
WO 9851705 A	19-11-1998	IT M1971105 A	12-11-1998
		AU 8016398 A	08-12-1998